Calcitriol ointment 3 μg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis

Cutis

Volumn 83, Issue 4, 2009, Pages 205-212

  Lebwohl, Mark ^a   Ortonne, Jean Paul ^b   Andres, Philippe ^c   Briantais, Philippe ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c Galderma R and D   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; VITAMIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; OINTMENT; PSORIASIS;

ADOLESCENT; CALCITRIOL; CHILD; FEMALE; HUMANS; MALE; OINTMENTS; PSORIASIS; VITAMINS;

EID: 66349115035     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64 (suppl 2):ii30-ii36.
2. Fall 2007 survey panel snapshot. National Psoriasis Foundation Web site. http://www.psoriasis.org/files/pdfs/research/2007_fall_survey_panel.pdf. Accessed July 14, 2008.
3. Statistics. National Psoriasis Foundation Web site. http: //www.psoriasis.org/about/stats/. Accessed July 14, 2008.
4. Dubertret L, Mrowietz U, Ranki A, et al. EUROPSO Patient Survey Group. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155:729-736.
5. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3, pt 1): 401-407.
6. Callen JP, Krueger GG, Lebwohl M, et al. AAD. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003;49:897-899.
7. Pearce DJ, Stealey KH, Balkrishnan R, et al. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol. 2006;45:370-374.
8. Afifi T, de Gannes G, Huang C, et al. Topical therapies for psoriasis: evidence-based review. Can Fam Physician. 2005;51:519-525.
9. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol. 2006;5:527-532.
10. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(1 suppl 1):S59-S69.
11. Lebwohl M, Ali S. Treatment of psoriasis. part 1. topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-498.
12. Ortonne JP, Humbert P, Nicolas JF, et al. Intraindividual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003;148:326-333.
13. Rizova E, Corroller M. Topical calcitriol-studies on local tolerance and systemic safety. Br J Dermatol. 2001;144(suppl 58):3-10.
14. Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol. 2007;6:428-435.
15. Barker JN, Berth-Jones J, Groves R, et al. Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis. J Dermatolog Treat. 2003;14:14-21.
16. Langner A, Ashton P, Van De Kerkhof PC, et al. A longterm multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol. 1996;135:385-389.
17. Queille-Roussel C, Duteil L, Parneix-Spake A, et al. The safety of calcitriol 3 microg/g ointment. evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity. Eur J Dermatol. 2001;11:219-224.